Quest PharmaTech Announces the Results of its January 26, 2010 AGM
TSX Venture: QPT
The Company is pleased to announce the following directors have been elected to the Company's Board of Directors:
Mr. Lorne Meikle, BA Mr. Ian McConnan, FCA, Mr. Paul Van Damme, CA Madi R. Madiyalakan, Ph.D., CEO
The Company also announced that its shareholders have approved the changes to the Company's stock option plan from a 10% rolling plan to a fixed plan with a maximum of 8,000,000 common shares available for issue under the fixed plan.
"We are pleased with the AGM results and wish to thank our shareholders for their continuing support," said
The Company also announced the granting of 250,000 stock options to independent Directors and 600,000 stock options to Officers, all at an exercise price of
Quest also announced that it has terminated the agreement it had with The Equicom Group Inc. ("Equicom") to provide strategic investor relations and corporate communications services to the Company. The Company wishes to express its sincere gratitude to Equicom for the services provided over the past 20 months. The Company has determined to in-source these initiatives on a going forward basis.
About Quest PharmaTech Inc.
Quest is an Alberta-based biotechnology company developing a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, photodynamic therapy, radioimmunotherapy or immunoadjuvants.
"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."
%SEDAR: 00008400E
For further information: For further information: Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: [email protected], Internet: www.questpharmatech.com
Share this article